ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI Imaging Device
Observational
Observational Model: Cohort, Time Perspective: Prospective
The sensitivities and specificities for the two (oral) doses of 5-ALA (15 mg/kg and 30 mg/kg) and control (0 mg/kg ALA) in differentiating cancer/normal tissue.
The sensitivity and specificity of fluorescence imaging for differentiating cancer from normal tissue in the breast will be evaluated by tissue histopathology and compared to standard white-light imaging. The sensitivities and specificities for auto-fluorescence (Cohort 1: 0 mg/kg 5-ALA) will be compared to the sensitivities and specificities of the two doses of 5-ALA (Cohort 2: 15mg/kg and Cohort 3: 30mg/kg). In addition, the sensitivities and specificities between the two 5-ALA dosing cohorts will be compared.
The fluorescence and white-light images will be evaluated and compared to histopathology within an average of 2 months after the surgery. The sensitivities and specificities will be calculated within 4 months of achieving a full dataset (45 patients).
Yes
Ralph S DaCosta, PhD
Principal Investigator
University Health Network, Toronto
Canada: Health Canada
10-0633-CE
NCT01837225
September 2010
May 2015
Name | Location |
---|